European Pharmaceuticals Analyst Turner provides an update on hidradenitis suppurativa as competition between NOVN & UCB heats up on an Analyst/Industry conference call to be held on November 11 at 10 am. Webcast Link
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on NOVN:
- Novan to Report Third Quarter 2022 Financial Results on November 14, 2022
- EPI Health, MC2 Therapeutics present data highlight WYNZORA technology
- EPI Health, a Novan Company, and MC2 Therapeutics Present New Data In Multiple Posters Highlighting WYNZORA’s® Unique PAD Technology™ at the 42nd Annual Fall Clinical Dermatology Conference®
- EPI Health, MC2 Therapeutics announce data from psoriasis survey
- EPI Health, a Novan Company, and MC2 Therapeutics Announce Data from Survey Conducted by National Psoriasis Foundation Presented at 42nd Annual Fall Clinical Dermatology Conference®